Porphyromonas gingivalis Cell Wall Components Induce Programmed Death Ligand 1 (PD-L1) Expression on Human Oral Carcinoma Cells by a Receptor-Interacting Protein Kinase 2 (RIP2)-Dependent Mechanism

被引:28
|
作者
Groeger, S. [1 ]
Denter, F. [1 ]
Lochnit, G. [2 ,3 ,4 ]
Schmitz, M. L. [2 ,3 ,4 ]
Meyle, J. [1 ]
机构
[1] Justus Liebig Univ Giessen, Dept Periodontol, Giessen, Germany
[2] Inst Biochem, Giessen, Germany
[3] German Ctr Lung Res, Giessen, Germany
[4] Justus Liebig Univ, Giessen, Germany
关键词
PD-L1; B7-H1; Porphyromonas gingivalis; immune evasion; immune suppression; signaling pathway; GASTRIC EPITHELIAL-CELLS; OUTER-MEMBRANE; B7-DC RECEPTORS; T-CELLS; B7-H1; NOD1; INNATE; PEPTIDOGLYCAN; SURAMIN; FAMILY;
D O I
10.1128/IAI.00051-20
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Programmed death-ligand 1 (PD-L1/B7-H1) serves as a cosignaling molecule in cell-mediated immune responses and contributes to chronicity of inflammation and the escape of tumor cells from immunosurveillance. Here, we investigated the molecular mechanisms leading to PD-L1 upregulation in human oral carcinoma cells and in primary human gingival keratinocytes in response to infection with Porphyromonas gingivalis (P. gingivalis), a keystone pathogen for the development of periodontitis. The bacterial cell wall component peptidoglycan uses bacterial outer membrane vesicles to be taken up by cells. Internalized peptidoglycan triggers cytosolic receptors to induce PD-L1 expression in a myeloid differentiation primary response 88 (Myd88)-independent and receptor-interacting serine/threonine-protein kinase 2 (RIP2)-dependent fashion. Interference with the kinase activity of RIP2 or mitogen-activated protein (MAP) kinases interferes with inducible PD-L1 expression.
引用
收藏
页数:13
相关论文
共 45 条
  • [41] Impact of Programmed Death-Ligand 1 (PD-L1) Expression on The Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKI) in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Lee, C. C.
    Soon, Y. Y.
    Leong, C. N.
    Koh, W. Y.
    Tey, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E137 - E137
  • [42] Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis
    Li, Yi-Ming
    Liu, Zhen-Yu
    Wang, Jian-Chao
    Yu, Jing-Min
    Li, Zhu-Chun
    Yang, Hai-Jiao
    Tang, Juan
    Chen, Zhi-Nan
    HEPATOLOGY, 2019, 70 (05) : 1564 - 1581
  • [43] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
    Xu, Rui-hua
    Kim, Sung-Bae
    Tougeron, David
    Zuo, Yunxia
    Yang, Haiyuan
    Zhang, Juan
    Shi, Jingwen
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [44] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).
    Xu, Rui-Hua
    Kim, Sung-Bae
    Tougeron, David
    Zuo, Yunxia
    Yang, Haiyuan
    Zhang, Juan
    Shi, Jingwen
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)
    Huang, Hui-qiang
    Tao, Rong
    Zou, Liqun
    Cen, Hong
    Guo, Ye
    Huang, Yunhong
    Qian, Wenbin
    Zhang, Liling
    Zhou, Hui
    Yang, Yu
    Yang, Haiyan
    Zhu, Dan
    Fang, Teng
    Dai, Hangjun
    Wang, Yueling
    Yang, Jianxin
    BLOOD, 2019, 134